Jasper Therapeutics surges on positive data from blood disorder drug trial

Jasper Therapeutics

03/01/2023 15:44

(Updates)
    ** Shares of biotech co Jasper Therapeutics Inc  JSPR.O  see
its highest-ever single-day pct gain, in opening trade of 2023  
    
    ** Stocks soar 400% to hit $2.4 in morning trade
    ** Co reports positive clinical trial data from first three
patients in early mid-stage study evaluating its investigational
drug briquilimab as a conditioning treatment for blood disorders
like sickle cell disease and beta thalassemia
    ** Conditioning treatment eliminates the underlying disease,
and prevents rejection of the new bone marrow by the body
    ** Two participants achieved 100% donor myeloid chimerism,
in which the body starts producing cells from donor's healthy
tissues, at 60 days post-transplant - co
    ** Briquilimab is being studied to potentially increase
percentage of healthy donor stem cell in body without increased
toxicity - JSPR
    ** Stock declined ~94% in 2022
 (Reporting by Aditya Samal)
 ((Aditya.Samal@thomsonreuters.com))